Katherine Giuliano1, Neeraja Nagarajan2, Joseph K Canner1, Christopher L Wolfgang1, Trinity Bivalacqua3, Stephanie Terezakis4, Joseph Herman4, Eric B Schneider5, Nita Ahuja6. 1. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 2. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Surgery, Brigham and Women's Hospital, Boston, MA. 3. Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Department of Radiation Oncology, Johns Hopkins University School of Medicine, Baltimore, MD. 5. Department of Surgery, Brigham and Women's Hospital, Boston, MA. 6. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: nahuja1@jhmi.edu.
Abstract
BACKGROUND: Retroperitoneal sarcomas are rare tumors that can be locally aggressive with high rates of recurrence. Given that data on survival in patients with retroperitoneal sarcomas are conflicting, we sought to use a nationwide cancer database to identify factors associated with survival in patients with retroperitoneal sarcomas. METHODS: The Surveillance, Epidemiology, and End Results database was utilized to identify patients with retroperitoneal sarcomas from 2002 to 2012. Univariable and multivariable survival analysis was performed using a generalized gamma parametric survival function. RESULTS: A total of 2,920 patients were included; overall 5- and 10-year survivals were 58.4% and 45.3%, respectively. On multivariable survival analysis, age, histologic type, grade, size, local extension, lymph node, and distant metastasis were associated with decreased survival (all P < .05). Patients undergoing operative resection survived 2.5 times longer (95% confidence interval: 2.0-3.0, P < .001) and those receiving radiation therapy 1.3 times longer (95% confidence interval: 1.1-1.6, P = .001), respectively. CONCLUSION: During the past decade, retroperitoneal sarcoma patients treated with radiation demonstrate longer survival compared with patients who did not receive radiation. Further study is needed to fully elucidate the mechanisms that underlie the radiation-related survival benefit observed in this study.
BACKGROUND:Retroperitoneal sarcomas are rare tumors that can be locally aggressive with high rates of recurrence. Given that data on survival in patients with retroperitoneal sarcomas are conflicting, we sought to use a nationwide cancer database to identify factors associated with survival in patients with retroperitoneal sarcomas. METHODS: The Surveillance, Epidemiology, and End Results database was utilized to identify patients with retroperitoneal sarcomas from 2002 to 2012. Univariable and multivariable survival analysis was performed using a generalized gamma parametric survival function. RESULTS: A total of 2,920 patients were included; overall 5- and 10-year survivals were 58.4% and 45.3%, respectively. On multivariable survival analysis, age, histologic type, grade, size, local extension, lymph node, and distant metastasis were associated with decreased survival (all P < .05). Patients undergoing operative resection survived 2.5 times longer (95% confidence interval: 2.0-3.0, P < .001) and those receiving radiation therapy 1.3 times longer (95% confidence interval: 1.1-1.6, P = .001), respectively. CONCLUSION: During the past decade, retroperitoneal sarcomapatients treated with radiation demonstrate longer survival compared with patients who did not receive radiation. Further study is needed to fully elucidate the mechanisms that underlie the radiation-related survival benefit observed in this study.
Authors: Sarah B Fisher; Yi-Ju Chiang; Barry W Feig; Janice N Cormier; Kelly K Hunt; Keila E Torres; Christina L Roland Journal: Am J Clin Oncol Date: 2019-02 Impact factor: 2.339
Authors: Thomas Malinka; Maxim Nebrig; Fritz Klein; Johann Pratschke; Marcus Bahra; Andreas Andreou Journal: BMC Surg Date: 2019-06-10 Impact factor: 2.102
Authors: Patrick B Schwartz; Kara Vande Walle; Emily R Winslow; Cecilia G Ethun; Thuy B Tran; George Poultsides; Jennifer Tseng; Kevin Roggin; Valerie Grignol; John Harrison Howard; Bradley A Krasnick; Ryan C Fields; Harveshp Mogal; Callisia N Clarke; Rebecca Senehi; Konstantinos Votanopoulos; Kenneth Cardona; Daniel E Abbott Journal: Sarcoma Date: 2019-06-02
Authors: Pippa F Cosper; Jeffrey Olsen; Todd DeWees; Brian A Van Tine; William Hawkins; Jeff Michalski; Imran Zoberi Journal: Radiat Oncol Date: 2017-12-08 Impact factor: 3.481